

1 Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a  
2 double-blind randomized, placebo-controlled, phase 2 trial  
3  
4 Marisa Holubar MD,<sup>1</sup> Aruna Subramanian MD,<sup>1</sup> Natasha Purington PhD,<sup>2</sup> Haley Hedlin PhD,<sup>2</sup>  
5 Bryan Bunning MS,<sup>2</sup> Katharine S. Walter PhD,<sup>1</sup> Hector Bonilla MD,<sup>1</sup> Athanasia Boumis,<sup>3</sup>  
6 Michael Chen MD,<sup>4</sup> Kimberly Clinton,<sup>3</sup> Liisa Dewhurst,<sup>3</sup> Carol Epstein MD,<sup>5</sup> Prasanna  
7 Jagannathan MD,<sup>1,6</sup> Richard H. Kaszynski MD,<sup>4</sup> Lori Panu,<sup>3</sup> Julie Parsonnet MD,<sup>1,7</sup> Elizabeth L.  
8 Ponder PhD,<sup>8</sup> Orlando Quintero MD,<sup>1</sup> Elizabeth Sefton PhD,<sup>8</sup> Upinder Singh MD,<sup>1,6</sup> Luke  
9 Soberanis,<sup>3</sup> Henry Truong PharmD,<sup>9</sup> Jason R. Andrews MD,<sup>1</sup> Manisha Desai PhD,<sup>2</sup> Chaitan  
10 Khosla PhD,<sup>10,8</sup> Yvonne Maldonado MD<sup>11,7</sup>

- 11 1. Division of Infectious Diseases and Geographic Medicine, Stanford University  
12 School of Medicine, Stanford, CA, USA
- 13 2. Quantitative Sciences Unit, Division of Biomedical Informatics Research,  
14 Department of Medicine, Stanford University, Palo Alto, CA, USA
- 15 3. Stanford Center for Clinical Research, Stanford University, Stanford, CA, USA
- 16 4. Stanford Solutions, Stanford University School of Medicine, Stanford, CA 94305,  
17 USA
- 18 5. Carol L. Epstein MD Consulting LLC, Wellington, FL, USA
- 19 6. Department of Microbiology and Immunology, Stanford University School of  
20 Medicine, Stanford, CA, USA
- 21 7. Department of Epidemiology and Population Health, Stanford University School  
22 of Medicine, Stanford, CA, USA
- 23 8. Stanford ChEM-H, Stanford University, Stanford CA, USA

- 24           9.     Mariner Advanced Pharmacy Corp, San Mateo, California  
25           10.    Departments of Chemistry and Chemical Engineering, Stanford University,  
26                    Stanford, CA, USA  
27           11.    Department of Pediatrics, Stanford University School of Medicine, Stanford, CA,  
28                    USA

29   **Keywords:** COVID-19, SARS-CoV-2, favipiravir, clinical trial

30   **Running title:** Favipiravir for uncomplicated COVID-19

31   **Correspondence:**

32   Marisa Holubar, MD MS  
33   Clinical Associate Professor of Medicine  
34   Division of Infectious Diseases and Geographic Medicine  
35   Stanford University School of Medicine  
36   300 Pasteur Drive, Lane Building 145  Stanford, CA 94305  
37   mholubar@stanford.edu

38  
39   **Alternate Correspondence:**

40   Aruna Subramanian, MD  
41   Clinical Professor of Medicine  
42   Division of Infectious Diseases and Geographic Medicine  
43   Stanford University School of Medicine  
44   300 Pasteur Drive, Lane Building 145  Stanford, CA 94305  
45   asubram2@stanford.edu

46 **Summary** In this phase 2 double-blind randomized controlled outpatient trial of favipiravir in  
47 asymptomatic or uncomplicated patients with COVID-19, we found no difference in time to  
48 shedding cessation or time to symptom resolution by treatment arm.

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65 **Abstract**

66 **Background:** Favipiravir is an oral, RNA-dependent RNA polymerase inhibitor with *in vitro*  
67 activity against SARS-CoV2. Despite limited data, favipiravir is administered to patients with  
68 COVID-19 in several countries.

69 **Methods:** We conducted a phase 2 double-blind randomized controlled outpatient trial of  
70 favipiravir in asymptomatic or mildly symptomatic adults with a positive SARS-CoV2 RT-PCR  
71 within 72 hours of enrollment. Participants were randomized 1:1 to receive placebo or favipiravir  
72 (1800 mg BID Day 1, 800mg BID Days 2-10). The primary outcome was SARS-CoV-2  
73 shedding cessation in a modified intention-to-treat (mITT) cohort of participants with positive  
74 enrollment RT-PCRs. Using SARS-CoV-2 deep sequencing, we assessed favipiravir's impact on  
75 mutagenesis.

76 **Results:** From July 8, 2020 - March 23, 2021, we randomized 149 participants with 116 included  
77 in the mITT cohort. The participants' mean age was 43 years (SD 12.5) and 57 (49%) were  
78 women. We found no difference in time to shedding cessation by treatment arm overall (HR  
79 0.76 favoring placebo, 95% confidence interval [CI] 0.48 – 1.20) or in sub-group analyses (age,  
80 sex, high-risk comorbidities, seropositivity or symptom duration at enrollment). We observed no  
81 difference in time to symptom resolution (initial: HR 0.84, 95% CI 0.54 – 1.29; sustained: HR  
82 0.87, 95% CI 0.52 – 1.45). We detected no difference in accumulation of transition mutations in  
83 the viral genome during treatment.

84 **Conclusions:** Our data do not support favipiravir use at commonly used doses in outpatients  
85 with uncomplicated COVID-19. Further research is needed to ascertain if higher doses of  
86 favipiravir are effective and safe for patients with COVID-19.

87 **Trial registration number:** NCT04346628

88

## 89 **Introduction**

90 Favipiravir is an oral, RNA-dependent RNA polymerase (RdRp) inhibitor with a wide spectrum  
91 of activity, including *in vitro* activity against SARS-CoV2. In its active form, favipiravir is  
92 incorporated into nascent viral RNA by error-prone viral RdRp and disrupts RNA synthesis  
93 directly by chain termination or accumulation of deleterious mutations in the SARS-COV-2  
94 genome.[1] Since 2014, favipiravir has been used in Japan and China for patients with drug-  
95 resistant influenza and boasts an established, well-characterized safety profile, making it an  
96 attractive potential therapeutic option for COVID-19.

97 Early data from some open-label trials suggested that favipiravir improved clinical and/or  
98 virologic outcomes in patients with COVID-19. [2, 3] Despite limited data, favipiravir was  
99 approved for use in patients with COVID-19 in some countries. We evaluated favipiravir's  
100 efficacy in reducing viral shedding duration and improving symptoms in outpatients with  
101 uncomplicated COVID-19.

## 102 **Methods**

### 103 **Study Design**

104 We conducted a Phase 2, double-blind, randomized, placebo-controlled phase 2 trial at Stanford  
105 Healthcare, California. Stanford University School of Medicine Panel on Human Subjects in  
106 Medical Research approved the study protocol. An independent Data and Safety Monitoring

107 Board (DSMB) reviewed the study design, clinical trial progress, study integrity, and safety data  
108 including interim analysis.

### 109 **Participants**

110 We enrolled asymptomatic or symptomatic adults without respiratory distress who had a positive  
111 SARS-CoV-2 RT-PCR collected within 72 hours of enrollment. We excluded individuals who  
112 required renal replacement therapy, had liver impairment, were immunocompromised or taking  
113 immunosuppressing medications, or were pregnant or breast-feeding.

114 Participants were randomized 1:1 to favipiravir or placebo using block, REDCap-implemented,  
115 randomization stratified by age ( $\geq 50$  and  $< 50$  years old) and sex. [4, 5]

### 116 **Procedures**

117 Participants received placebo or favipiravir at doses of 1800 mg BID on Day 1, then 800mg BID  
118 on days 2-10. Favipiravir and placebo tablets were identical in appearance to maintain blinding.

119 We followed participants for 28 days and performed a clinical assessment and collected  
120 oropharyngeal (OP) swabs and blood samples at each visit. Staff-collected OP specimens  
121 underwent a reverse-transcription polymerase chain reaction assay (RT-PCR) (Viroclinics  
122 Biosciences, Rotterdam, The Netherlands). Anti-SARSCoV-2 serology was performed using a  
123 virus plaque reduction neutralization assay (Viroclinics Biosciences, Rotterdam, The  
124 Netherlands).

125 Patients self-collected daily anterior nasal swabs on days 1-10, 14, 21, and 28 and submitted  
126 them directly for RT-PCR testing with an assay that targeted the viral nucleocapsid gene's N1  
127 and N3 regions (Quest Diagnostics, Secaucus, New Jersey).

128 Patients also completed electronic daily symptom surveys and recorded temperature and oxygen  
129 saturation using study-provided devices; all data was collected using REDCap Cloud version 1.6  
130 (REDCap Cloud, Encinitas, California).

### 131 **Outcomes**

132 We defined the primary outcome, SARS-CoV-2 shedding cessation, as the time from enrollment  
133 to the first of two consecutive negative nasal RT-PCRs. We defined time until initial resolution  
134 of symptoms as time from randomization until the first of two consecutive days without  
135 symptoms. We defined time until sustained symptom resolution similarly, with the additional  
136 condition that symptoms remain resolved throughout the remainder of the study. Decreased  
137 taste/smell, mild fatigue, and mild cough were recorded, but excluded as symptoms for this  
138 analysis.[6] We censored participants who did not meet the symptom endpoint on their last  
139 completed survey. Additional secondary outcomes included incidence of hospitalizations or  
140 emergency department visits during the study and adverse events graded for severity.[7]

### 141 **Sample qPCR testing and sequencing protocols**

142 To test whether favipiravir was acting as a mutagen, one of its mechanisms of action [1], we  
143 deep sequenced SARS-CoV-2 from residual day 1, 5 and 10 participant nasal swabs using an  
144 Illumina MiSeq platform (Supplementary Methods).

### 145 **Statistical analysis**

146 We assessed virologic outcomes in a modified intention-to-treat (mITT) cohort, which included  
147 all randomized participants whose first available nasal RT-PCR result on days 1-3 was positive.  
148 We assessed symptom outcomes in a symptomatic (smITT) cohort, which included all  
149 randomized participants who reported at least one symptom at enrollment that was not mild

150 cough, mild fatigue, or decreased taste/smell. We assessed safety endpoints in the ITT cohort.

151 All analyses adjusted for age group and sex. Unless otherwise noted, all tests were two-sided and

152 conducted at an alpha level of 0.05. Analyses were performed in R version 4.0.2.[4, 5]

153 *Primary analysis.* We used a Cox proportional hazards model to compare time until shedding

154 cessation between treatment arms. The final test was performed at the  $\alpha = 0.04999$  level of

155 significance allowing for an interim analysis. We censored participants who did not meet the

156 endpoint on the last positive PCR result date and verified the proportional hazards assumption by

157 examining Schoenfeld residuals.

158 *Secondary analyses.* We used a Cox proportional hazards model to compare initial and sustained

159 symptom resolution between arms and Fisher's Exact test to compare proportions.

160 We evaluated change in Cycle Threshold (Ct) from Day 1 to Day 7 and from Day 1 to Day 10 by

161 treatment arm using generalized linear mixed effects regression models (GLMM, Supplementary

162 Methods).

163 *Post-hoc and efficacy sensitivity analyses.* We added a statistical interaction term between

164 treatment and these baseline characteristics to the primary efficacy model to test for effect

165 modification: seropositivity; high-risk status; symptom onset within 3, 5, and 7 days of

166 enrollment; age group; sex. We classified participants as high risk if they met any of these

167 criteria:  $\text{age} \geq 65$ ,  $\text{BMI} \geq 35$ , chronic kidney disease, diabetes mellitus, or  $\text{age} \geq 55$  and with one

168 of these comorbidities: cardiovascular disease, hypertension, or chronic respiratory disease.

169 Interaction terms were also added to the sustained symptom resolution model for high-risk status

170 and symptom onset within 3 and 5 days of enrollment. We reported p-values from a Wald test

171 corresponding to the interaction terms and within-subgroup hazard ratios.



172 *Sample size determination.* Assuming 1:1 randomization and a two-sided log rank test at  
173  $\alpha = 0.04999$  level of significance for the final analysis, we anticipated 79 shedding  
174 cessation events, which provided 80% power to detect a hazard ratio of 2.03. We additionally  
175 assumed median of 14 days to shedding cessation in the control arm and 7 days in the treatment  
176 arm, a 3-month accrual period, a 4-week follow-up period after randomization of the last patient,  
177 and 10% drop out in the control arm. This enabled an interim analysis conducted at  
178  $\alpha = 0.00001$  to assess overwhelming efficacy after 50% of participants completed  
179 24 hours of follow-up. We estimated that the total sample size required to achieve 79 events  
180 was 120 (60 participants per arm).

181 At interim review, the DSMB recommended increasing the sample size with the goal of 120  
182 participants in the mITT cohort.

### 183 **Variant identification**

184 We used the nfcov/viralrecon v.2.3dev bioinformatic pipeline to perform variant calling and to  
185 generate consensus sequences from raw reads (Supplementary Methods).[8] We predicted that  
186 favipiravir would impact viral diversity by study day 5 and result in a higher rate of transition  
187 mutations. [1, 9]

188 To assess favipiravir's impact on SARS-CoV-2 within-host diversity, we tested if the number of  
189 iSNVs, transitions, and/or either iSNVs and transitions standardized by the total number of bases  
190 sequenced in a sample differed between the treatment arms on day 5 using one-sided two-sample  
191 t-tests with the R package rstatix.[10] We fit independent linear models for the number of  
192 iSNVs, standardized number of iSNVs, number of transitions, and standardized number of  
193 transitions with study day and treatment group as predictor variables in the R package stats.[11]

194 We used a p-value threshold of 0.05 to identify predictors significantly associated with within-  
195 host viral diversity.

## 196 **Results**

197 From July 8, 2020 through March 23, 2021, we screened 385 patients and randomized 149  
198 patients who were included in the ITT cohort (74 placebo, 75 favipiravir; Figure 1). Of these,  
199 116 participants were included in the mITT and 135 in the smITT cohorts; 112 participants were  
200 included in all 3 analytic cohorts (Supplementary Figure 1).

201 Baseline demographic and disease characteristics were balanced between the two groups in all  
202 analytic cohorts (Table 1). In the mITT cohort, 31% of participants had at least one comorbidity  
203 of interest, and 37% had a body mass index  $\geq 30$ . Of those with a positive RT-PCR upon  
204 enrollment, the median Ct was 24 [IQR 21-28] for the N1 target and only 10 participants had  
205 detectable antibodies (placebo 4, favipiravir 6).

## 206 **Primary Analysis**

207 Of the mITT population, 79 participants met the primary endpoint (44/57 [77%] placebo versus  
208 35/59 [59%] favipiravir). Although the likelihood of shedding cessation favored placebo, we  
209 found no statistically significant difference in time to shedding cessation by treatment arm (HR  
210 0.76, 95% confidence interval [CI] 0.48 – 1.20, P-value =0.24; Figure 2). We detected no  
211 difference in median time to shedding cessation between groups (placebo: 13 days (95% CI 9 –  
212 14) versus favipiravir: 14 days (95% CI 9 – 21) Table 2). Of the 37 participants who did not  
213 meet the primary outcome, 18 had at least one negative RT-PCR during the study (8 placebo, 10  
214 favipiravir).

215 In pre-specified and post-hoc analyses, we found no difference in time to shedding cessation by  
216 sub-groups including age group, sex, high risk comorbid conditions, seropositivity or duration of  
217 symptoms at enrollment (Supplementary Table 1).

218 In a sensitivity analysis using the ITT cohort, the median time to shedding cessation decreased to  
219 9 days for both arms.

## 220 **Secondary Analyses**

221 In the smITT population, both groups reported a median of 5 days of symptoms at enrollment  
222 (Table 1). The most common symptoms included cough/dyspnea, fatigue, myalgias, and  
223 headache.

224 We found no statistically significant difference in time to initial or sustained symptom resolution  
225 by treatment arm (initial: HR 0.84, 95% CI 0.54 – 1.29; sustained: HR 0.87, 95% CI 0.52 – 1.45;  
226 Table 2, Figure 2). The median time to initial symptom resolution was 1 day shorter in the  
227 placebo arm (14 days; 95% CI 11 – 18 versus 15 days; 95% CI 12 – 26). Although participants  
228 reported fewer and milder symptoms over time, 30 participants (18 placebo, 12 favipiravir)  
229 continued to report at least 1 symptom on day 28 (Figure 3, Supplementary Figures 3 and 4).

230 In the ITT cohort, 12 participants reported at least one emergency room visit during the study (7  
231 (9.5%) placebo versus 5 (6.7%) favipiravir,  $p=0.56$ ). Four were hospitalized and all 4 received  
232 placebo (Table 2).

233 Of the 124 randomized participants who did not have detectable antibodies at baseline, 71 (57%)  
234 were seropositive at day 28 (Supplementary Table 2).

## 235 **Virologic Analyses**

236 Although the average Ct values increased significantly over time, the magnitude of decline did  
237 not differ between treatment arms (Figure 4, Supplementary Figure 2). We found no difference  
238 in the proportion of participants in either arm with a negative nasal RT-PCR on days 7 or 10 or a  
239 negative oropharyngeal RT-PCR on days 5 and 28 (Table 2, Supplementary Table 2).

#### 240 **Adverse Events**

241 More participants reported adverse events in the favipiravir arm, but this difference was not  
242 statistically significant (10/71 (13.5%) in placebo vs. 19/75 (25.3%) in favipiravir arm;  $p=0.11$ ;  
243 Table 2). The most common adverse event reported by those who received favipiravir was  
244 dizziness. More participants in the favipiravir arm developed hyperuricemia on study day 10  
245 (placebo 21/71; 30% versus favipiravir 54/66; 82%) but only 3 participants were symptomatic.

#### 246 **Sequencing Analyses**

247 We included 112 PCR-positive nasal samples from 73 study participants (36 placebo, 37  
248 favipiravir) that met our quality and coverage filters, including >1 longitudinal sample from 36  
249 participants (18 placebo, 18 favipiravir). Residual nasal swabs had a mean qPCR CT of 22.3 and  
250 a mean depth of coverage of 1738X (95.1% of the genome with depth of coverage >10X).

251 SARS-CoV-2 variation observed within a representative participant is shown in Supplementary  
252 Figure 5.

253 On day 5, we found no difference in the mean low frequency intrahost single nucleotide variants  
254 (iSNVs) in either arm (favipiravir 26.7 (std 16.5) versus placebo 37.4 (std 32.6),  $p=0.23$ , two-  
255 sided t-test; Supplementary Figure 6). After standardizing by sequencing effort, the mean  
256 number of iSNVs was higher in the favipiravir (mean:  $3.09 \times 10^{-8}$  iSNVs/sequenced base-pairs;

257 std:  $3.24 \times 10^{-8}$ ) compared to the placebo arm (mean:  $2.1 \times 10^{-8}$  iSNVs/bp; std:  $2.03 \times 10^{-8}$ ), but this  
258 difference was not significant ( $p = 0.35$ , two-sided t-test).

259 We found no difference in the number of transition iSNVs ( $p = 0.28$ , two-sided t-test) or the  
260 number of transition iSNVs standardized by sequencing effort ( $p = 0.37$ , two-sided t-test) in those  
261 who received favipiravir compared to placebo.

262 Finally, in linear models, we did not find that treatment arm was significantly associated with  
263 within-host SARS-CoV-2 diversity as measured by the raw number of iSNVs, the number of  
264 transition iSNVs, or the number of raw or transition iSNVs standardized by sequencing  
265 throughput, after controlling for study day.

## 266 **Discussion**

267 In this trial of outpatients with asymptomatic or mild COVID-19, we found no difference in time  
268 to shedding cessation or symptom resolution between the favipiravir and placebo group.

269 Our results differ from previous open-label studies, possibly due to the added rigor of blinding  
270 and the robust data collection in our study. In an open-label favipiravir trial in India, Udawadia et  
271 al found no difference in time to viral shedding cessation using both oropharyngeal and  
272 nasopharyngeal swabs, however they did report a difference in time to clinical cure based on un-  
273 blinded clinician assessments of fever, oxygen saturation, and cough.[2] Our clinical symptom  
274 evaluation was more rigorous involving daily surveys which included a broader range of  
275 COVID-19 symptoms. In an open-label randomized controlled trial, Doi et al compared early  
276 (day 1) and late (day 6) favipiravir initiation and found a difference in fever resolution by day 2,  
277 but no difference in time to fever resolution or viral shedding.[12] In another open-label  
278 randomized controlled trial, Ivashenko et al found a difference in viral clearance by day 5 when

279 they compared two favipiravir dosing regimens to standard of care, but this became equivalent  
280 by day 10.[3] Although we used a different primary outcome of time to shedding cessation as  
281 defined by 2 negative nasal RT-PCR tests, we also observed no difference in changes in RT-PCR  
282 Ct from day 1 to days 5 and 7.

283 To ensure robust outcomes, our study targeted those who were most likely to benefit from  
284 antiviral therapy by enrolling patients early in their illness. Overall, the median time from  
285 symptom onset to randomization was only 5 days, and in our mITT cohort only 10 out of 116  
286 participants had developed anti-spike IgG at enrollment. Despite early favipiravir administration,  
287 we found no difference in either virologic or clinical outcomes.

288 We used the same favipiravir dosing regimen as other trials investigating favipiravir for COVID-  
289 19. [2, 3] In fact, some trials used the lower dosing regimen that is approved for patients with  
290 pandemic influenza in Japan. [13, 14] However, it is possible that this regimen did not achieve  
291 adequate levels to inhibit viral replication. A recent dose-optimizing study of 19 critically ill  
292 patients with influenza demonstrated a decrease in plasma trough concentrations ( $C_{\text{trough}}$ ) during  
293 the treatment course, estimating that only 42% of patients who received favipiravir 1800mg BID  
294 followed by 800 mg BID achieved the goal  $C_{\text{trough}}$  of  $\geq 20$  mg/L for  $>80\%$  of the treatment  
295 duration.[15] Modeling from this work suggested that regimens of  $\geq 3600$  mg loading dose  
296 followed by 2600 mg might be necessary to achieve target concentrations. Trials investigating  
297 favipiravir for the treatment of Ebola used higher doses of favipiravir (6000mg/day load, then  
298 2400mg/day), but also achieved lower drug concentrations than predicted at days 2 and 4 of  
299 treatment and did not meet their clinical endpoint.[16]

300 Suboptimal dosing may also explain why we found no evidence of mutagenesis after at least 5  
301 days of favipiravir exposure. Our findings differ from *in vitro* work demonstrating a three-fold

302 increase in the total number of mutations and twelve-fold increase in C to T or G to A transitions  
303 in Vero cells infected with SARS-CoV-2 exposed to favipiravir compared to controls.[1] This is  
304 also in contrast to a recent *in vivo* study of molnupiravir, a closely related nucleotide analogue,  
305 that found a two-fold increase in mutations in the SARS-COV-2 RdRp gene in the treatment  
306 compared to the control group.[17] A study that evaluated favipiravir dosing for Ebola infections  
307 in macaques found that viral mutational load was strongly associated with favipiravir dose[9]  
308 and that the accumulation of viral mutations was associated with lower levels of plasma  
309 infectious viral particles. Based upon these findings, the authors suggested that an earlier clinical  
310 trial in humans may have used suboptimal favipiravir dosing.

311 In contrast to our findings, an ongoing randomized placebo-controlled trial of molnupiravir—a  
312 nucleoside analog-prodrug-- has reported a 50% reduction in COVID-19 related  
313 hospitalizations.[18] The overall hospitalization rates were higher than in our favipiravir study,  
314 possibly due to differences in standards of care and the predominance of SARS-CoV-2 B.1.617  
315 (Delta variant) during the molnupiravir study. Of note, *in vitro* data suggests molnupiravir may  
316 also be mutagenic to mammalian cells.[19] Animal studies suggest that favipiravir administered  
317 in combination with molnupiravir may be an effective strategy to allow for lower molnupiravir  
318 doses and potentially avoid unintended consequences.[20]

319 Our study has several limitations. Most therapeutic studies for COVID-19, like ours, assess  
320 antiviral efficacy by using RT-PCR to detect viral RNA from nasal, nasopharyngeal or  
321 oropharyngeal swabs. However, detectable RNA may not reflect actively replicating virus and  
322 individuals can continue to have detectable RNA intermittently and long after illness  
323 recovery.[21] Widespread use of cell culture to detect replication-competent virus and to  
324 establish viral clearance is limited by feasibility, cost, and safety considerations.[21] Although

325 we use cycle threshold rather than viral load, our analysis was strengthened by serial testing from  
326 individuals. Our primary endpoint was based upon participant-collected nasal swabs, which may  
327 be less accurate than nasopharyngeal swabs.[22] However, we found similar results from a  
328 secondary analysis of study staff collected oropharyngeal swabs. Our study was powered to  
329 detect differences in shedding cessation, not symptom resolution. Our study was not designed to  
330 detect a difference in long COVID syndrome, but we found that nearly half of both favipiravir  
331 and placebo-treated patients continued to report symptoms 28-day after enrollment. Finally, our  
332 study enrolled patients prior to the emergence and dominance of SARS-CoV-2 B.1.617 (Delta  
333 variant) in the US.

334 In conclusion, our data do not support favipiravir use at currently recommended doses in  
335 outpatients with mild or asymptomatic COVID-19. Dose optimization studies are necessary to  
336 elucidate if favipiravir administered at higher doses or delivered in combination with other  
337 agents is effective and safe for patients with COVID-19.

338

339

340

341

342

### 343 **Acknowledgements**

344 We sincerely thank all participants for generously volunteering for this study and all study staff  
345 for their tireless effort and enthusiasm, including Renu Verma and Eugene Kim. We also thank



346 our partners in Stanford Healthcare, Stanford University Occupational Health and San Mateo  
347 Medical Center in assisting in recruitment, Stanford University leadership for providing research  
348 space, and the DSMB members for their service. The study was funded by anonymous donors to  
349 Stanford University.

350 The Stanford REDCap platform (<http://redcap.stanford.edu>) is developed and operated by  
351 Stanford Medicine Research IT team. The REDCap platform services at Stanford are subsidized  
352 by a) Stanford School of Medicine Research Office, and b) the National Center for Research  
353 Resources and the National Center for Advancing Translational Sciences, National Institutes of  
354 Health, through grant UL1 TR001085. The Quantitative Sciences Unit is partially supported by  
355 UL1 TR003142.

356 **Funding:** This work was supported by anonymous donors to Stanford University. The funders  
357 had no role in data collection, analysis, or the decision to publish.

358

359

360

361

362

363

364

365

366

367 **References**

- 368 1. Shannon A, Selisko B, Le NT, et al. Rapid incorporation of Favipiravir by the fast and  
369 permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.  
370 Nat Commun **2020**; 11(1): 4682.
- 371 2. Udwardia ZF, Singh P, Barkate H, et al. Efficacy and safety of favipiravir, an oral RNA-  
372 dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized,  
373 comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis **2021**; 103: 62-  
374 71.
- 375 3. Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for Treatment of  
376 Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a  
377 Phase II/III Multicenter Randomized Clinical Trial. Clin Infect Dis **2021**; 73(3): 531-4.
- 378 4. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an  
379 international community of software platform partners. J Biomed Inform **2019**; 95:  
380 103208.
- 381 5. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic  
382 data capture (REDCap)--a metadata-driven methodology and workflow process for  
383 providing translational research informatics support. J Biomed Inform **2009**; 42(2): 377-  
384 81.
- 385 6. United States Department of Health and Human Services; Food and Drug Administration.  
386 Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in  
387 Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment:  
388 Guidance for Industry, **2020**.

- 389 7. Trotti A, Colevas A, Setser A, et al. CTCAE v3.0: development of a comprehensive  
390 grading system for the adverse effects of cancer treatment. *Seminars in Radiation  
391 Oncology* **2003**; 13(3): 176-81.
- 392 8. Ewels PA, Peltzer A, Fillinger S, et al. The nf-core framework for community-curated  
393 bioinformatics pipelines. *Nat Biotechnol* **2020**; 38(3): 276-8.
- 394 9. Guedj J, Piorkowski G, Jacquot F, et al. Antiviral efficacy of favipiravir against Ebola  
395 virus: A translational study in cynomolgus macaques. *PLoS Med* **2018**; 15(3): e1002535.
- 396 10. Kassambara A. rstatix: Pipe-Friendly Framework for Basic Statistical Tests. R package  
397 version 0.6.0. Available at: <https://CRAN.R-project.org/package=rstatix>
- 398 11. Team RC. R: A language and environment for statistical computing. Vienna, Austria,  
399 **2019**
- 400 12. Doi Y, Hibino M, Hase R, et al. A Prospective, Randomized, Open-Label Trial of Early  
401 versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. *Antimicrob  
402 Agents Chemother* **2020**; 64(12).
- 403 13. Lou Y, Liu L, Yao H, et al. Clinical Outcomes and Plasma Concentrations of Baloxavir  
404 Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized,  
405 Controlled Trial. *Eur J Pharm Sci* **2021**; 157: 105631.
- 406 14. Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19:  
407 An Open-Label Control Study. *Engineering (Beijing)* **2020**; 6(10): 1192-8.
- 408 15. Wang Y, Zhong W, Salam A, et al. Phase 2a, open-label, dose-escalating, multi-center  
409 pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients  
410 with severe influenza. *EBioMedicine* **2020**; 62: 103125.

- 411 16. Sissoko D, Laouenan C, Folkesson E, et al. Experimental Treatment with Favipiravir for  
412 Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-  
413 Concept Trial in Guinea. *PLoS Med* **2016**; 13(3): e1001967.
- 414 17. Fischer W, Eron JJ, Holman W, et al. Molnupiravir, an Oral Antiviral Treatment for  
415 COVID-19. *medRxiv* **2021**.
- 416 18. Merck & Co. I. Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir  
417 Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to  
418 Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of  
419 Phase 3 Study. **2021**.
- 420 19. Zhou S, Hill CS, Sarkar S, et al. beta-d-N4-hydroxycytidine Inhibits SARS-CoV-2  
421 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. *J Infect Dis*  
422 **2021**; 224(3): 415-9.
- 423 20. Abdelnabi R, Foo CS, Kaptein SJF, et al. The combined treatment of Molnupiravir and  
424 Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster  
425 infection model. *EBioMedicine* **2021**; 72: 103595.
- 426 21. Jefferson T, Spencer EA, Brassey J, Heneghan C. Viral cultures for COVID-19 infectious  
427 potential assessment - a systematic review. *Clin Infect Dis* **2020**.
- 428 22. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. Performance of Saliva,  
429 Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: a  
430 Systematic Review and Meta-analysis. *J Clin Microbiol* **2021**; 59(5).

431

432

433

434 **Figure Legends**

435 **Figure 1. CONSORT diagram**

436 Trial schematic showing participants screened, randomized, and followed through study  
437 completion.

438 **Figure 2. Kaplan–Meier analyses of the primary and key secondary outcomes in the**  
439 **modified intention-to-treat population**

440 Time until a) shedding cessation of SARS-CoV-2 in RT-PCR from nasal swabs; b) initial  
441 symptom resolution; c) sustained symptom resolution stratified by treatment arm, favipiravir  
442 (red) vs. placebo (gray). Participants who did not experience the endpoint were censored (+  
443 symbol) at their last positive swab for the primary outcome or at the last completed symptom  
444 questionnaire for the key secondary outcomes. Solid lines represent Kaplan–Meier survival  
445 probability; shading represents 95% confidence intervals.

446 **Figure 3. Symptom prevalence in the symptomatic modified intention-to-treat population**

447 Mirrored bar plots of percentage of smITT participants reporting symptoms by treatment arm  
448 and study day, colored by symptom severity. Numerator is the number of participants reporting  
449 the symptom severity per study day and treatment arm; denominator is the number of overall  
450 participants in the treatment arm (n=70 in placebo and n=65 in favipiravir). Symptoms are  
451 ordered by Day 1 relative frequency within their respective organ systems (lower respiratory,  
452 upper respiratory, systemic, gastrointestinal, other). Bars to the right of the centered black line  
453 represent favipiravir symptom distributions, while those on the left are representative of placebo.

454 **Figure 4. Trajectory of nasal cycle threshold in the modified intention-to-treat population**

455 Line plots of nasal cycle threshold (Ct) values over time by treatment arm. Each dot represents  
456 the mean Ct value on that study day by treatment arm; bars represent the standard error around  
457 the mean. Lines are slightly jittered to avoid overlap. The red horizontal line at  $y=40$  represents  
458 the limit of detection. Y-axis is reversed so that lower values of Ct represent more virus detected.

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474 **Table 1.** Baseline characteristics

	mITT (n=116)			smITT (n=135)		
	Placebo (n=57)	Favipiravir (n=59)	SMD	Placebo (n=70)	Favipiravir (n=65)	SMD
<b>Age at randomization in years, mean (SD)</b>	43.4 (12.8)	42.9 (12.3)	0.04	42.8 (12.6)	42.5 (12.0)	0.03
<b>Female, n (%)</b>	29 (50.9)	28 (47.5)	0.07	37 (52.9)	32 (49.2)	0.07
<b>Race/ethnicity, n (%)</b>			0.14			0.20
Latinx	24 (42.1)	26 (44.1)		29 (41.4)	28 (43.1)	
White	21 (36.8)	19 (32.2)		26 (37.1)	22 (33.8)	
Asian	5 (8.8)	6 (10.2)		7 (10.0)	6 (9.2)	
Native Hawaiian/ Pacific Islander	1 (1.8)	2 (3.4)		1 (1.4)	3 (4.6)	
Other/Unknown	6 (10.5)	6 (10.2)		7 (10.0)	6 (9.2)	
<b>Mean body mass index (BMI) (SD)</b>	29.3 (6.0)	27.8 (5.7)	0.25	28.9 (5.9)	28.0 (5.8)	0.15
<b>BMI 30+, n (%)</b>	25 (43.9)	18 (30.5)	0.33	29 (41.4)	21 (32.3)	0.19
<b>Number with comorbid conditions, n (%)</b>						
None	39 (68.4)	41 (69.5)	0.02	48 (68.6)	47 (72.3)	0.08
Diabetes Mellitus	3 (5.3)	7 (11.9)	0.24	4 (5.7)	8 (12.3)	0.23
Hypertension	5 (8.8)	5 (8.5)	0.01	8 (11.4)	6 (9.2)	0.07
Chronic lung disease	3 (5.3)	2 (3.4)	0.09	3 (4.3)	2 (3.1)	0.06
<b>Asymptomatic, n (%)</b>	1 (1.8)	3 (5.1)	0.18	0	0	<0.01
<b>Days from symptom onset to randomization, median [IQR]</b>	5 [4, 6]	5 [3, 7]	0.01	5 [4, 7]	5 [3, 7]	0.08
<b>Number of symptoms reported at randomization, median [IQR]</b>	6 [4, 9]	6 [4, 8.5]	0.28	6 [4, 9]	6 [4, 8]	0.16
<b>Symptoms at randomization, n (%)</b>						
Fever	2 (3.5)	1 (1.7)	0.11	3 (4.3)	1 (1.5)	0.16
Cough/Dyspnea	44 (77.2)	42 (71.2)	0.14	48 (68.6)	47 (72.3)	0.08
Fatigue	41 (71.9)	40 (67.8)	0.09	51 (72.9)	47 (72.3)	0.01
Joint pain	18 (31.6)	20 (33.9)	0.05	20 (28.6)	22 (33.8)	0.11
Myalgias	36 (63.2)	36 (61.0)	0.04	42 (60.0)	38 (58.5)	0.03
Headache	37 (64.9)	40 (67.8)	0.06	45 (64.3)	43 (66.2)	0.04
<b>Received at least one dose of COVID-19 vaccine, n (%)</b>	2 (3.5)	0 (0.0)	0.27	2 (2.9)	0 (0.0)	0.24
<b>Baseline seropositivity, n (%)</b>	4 (7.0)	6 (10.2)	0.30	11 (15.7)	9 (13.8)	0.14

<b>Baseline anterior nares RT-PCR Ct, median, [IQR]</b>	25.1 [22.2, 28.9]	22.2 [19.7, 27.2]	0.30	28.3 [23.2, 38.4]	24.3 [20.7, 31.9]	0.38
<b>Baseline oropharyngeal RT-PCR positivity, n (%)</b>	50 (87.7)	54 (91.5)	0.18	52 (74.3)	53 (81.5)	0.24
<b>Baseline laboratory values, median [IQR]</b>						
AST (units/L)	32.0 [26.0, 42.5]	29.0 [25.0, 34.0]	0.39	29.5 [25.8, 39.3]	29.0 [25.0, 34.0]	0.31
ALT (units/L)	29.0 [20.0, 48.0]	25.0 [19.5, 38.0]	0.18	24.5 [18.8, 46.5]	25.0 [19.0, 37.0]	0.16
Creatinine (mg/dL)	0.8 [0.6, 1.0]	0.8 [0.6, 1.0]	0.09	0.8 [0.7, 1.0]	0.8 [0.6, 1.0]	0.12
Uric acid (mg/dL)	4.5 [3.5, 5.8]	4.4 [3.9, 5.3]	<0.01	4.5 [3.5, 5.6]	4.4 [3.9, 5.3]	0.02

475 SMD = standardized mean difference; IQR = inner quartile range; Ct = cycle threshold



**Table 2.** Primary and Secondary Outcomes

	Treatment arm		Measure of association	
	Placebo	Favipiravir	aHR (95% CI)	p-value
<b>Primary Outcome<sup>2</sup></b>				
Days until viral shedding cessation, median (95% CI)	13 (9, 14)	14 (9, 21)	0.76 (0.48, 1.20)	0.24
<b>Secondary Clinical Outcomes</b>				
Hospitalizations by Day 28 <sup>1</sup> , n participants (%)	4/74 (5)	0	.	0.06
Emergency Department visits by Day 28 <sup>1</sup> , n participants (%)	7/74 (10)	5/75 (7)	.	0.56
Days until initial resolution of symptoms <sup>3</sup> , median (95% CI)	14 (11, 18)	15 (12, 26)	0.84 (0.54, 1.29)	0.43
Days until sustained resolution of symptoms <sup>3</sup> , median (95% CI)	24 (21, NA)	NA (26, NA)	0.87 (0.52, 1.45)	0.59
<b>Secondary Virologic Outcomes<sup>2</sup></b>			<b>Δ inverse Ct (95% CI)</b>	<b>p-value</b>
Change in reverse Ct from Day 1 to 7, mean (SD)	-7.0 (5.6)	-9.2 (5.0)	-2.06 (-4.34, 0.22)	0.08
Change in reverse Ct from Day 1 to 10, mean (SD)	-10.5 (5.1)	-12.9 (5.9)	-1.83 (-4.19, 0.53)	0.13
Negative by RT-PCR on Day 7, n participants (%)	10/47 (21)	10/42 (24)	.	0.80
Negative by RT-PCR on Day 10, n participants (%)	23/45 (51)	20/35 (57)	.	0.65
<b>Safety Outcomes<sup>1</sup></b>				
Serious Adverse Events, n events (%)	1 (1.4)	0	.	
Resulting in death	0	0	.	
Resulting in hospitalization	1 (100.0)	0	.	
Adverse Events, n events	15	27	.	
Adverse Events, n participants (%)	10 (13.5)	19 (25.3)	.	0.11
Grade 3 Adverse Events, n (%)	2 (13.3)	2 (7.4)	.	
Most common adverse events, n participants (%)				
Dizziness	2 (2.7)	3 (4.0)	.	

Nausea	3 (4.1)	1 (1.3)	.	
Day 10 uric acid (mg/dL), median (IQR)	4.9 (4.1, 6.0)	7.4 (6.3, 9.0)	.	

<sup>1</sup> among the intention-to-treat (ITT) population.

<sup>2</sup> among the modified ITT population.

<sup>3</sup> among the symptomatic ITT population.

<sup>4</sup> among ITT population who were not seropositive at enrollment.

NA = undefined; aHR = adjusted hazard ratio (adjusted for age 50+ and sex); CI = confidence interval; Ct = cycle threshold; OP = oropharyngeal; RT-PCR = reverse transcription-polymerase chain reaction. All virologic endpoints use anterior nares swab results unless otherwise stated.

Figure 1






Figure 2



**Number at risk**

Treatment	0	3	6	9	12	15	18	21	24	27
Placebo	57	53	49	39	26	12	9	8	1	1
Favipiravir	59	52	46	36	21	9	9	9	1	1


Days from randomization



**Number at risk**

Treatment	0	3	6	9	12	15	18	21	24	27
Placebo	70	64	60	50	36	25	21	18	15	14
Favipiravir	65	58	54	43	35	27	21	19	15	10

Days from randomization



**Number at risk**

Treatment	0	3	6	9	12	15	18	21	24	27
Placebo	70	67	66	60	53	46	41	36	30	24
Favipiravir	65	60	57	51	45	38	36	35	29	20

Days from randomization

Figure 3




Figure 4

